A new Frontiers in Immunology review from Ong, Wincup and colleagues, shows that lupus arthropathy is not a single uniform entity and it is biologically under-studied and clinically mismeasured, Moreover, the biology of lupus arthritis may shed light on choosing the best therapy for MSK manifestations of SLE.
Recent News
As the leaves start changing color and spooky decorations populate neighborhood doorsteps, another autumnal tradition begins: vaccination counseling. Fall offers a golden opportunity to protect our patients before respiratory viruses fill our waiting rooms. In patients with rheumatologic diseases, vaccinations can be confusing and worrisome. For clinicians with limited bandwidth, these conversations can feel like added responsibilities in an already overfull schedule.Read Article
article
Dr. John Cush
Tweet
Thai study of opportunistic infx in Pediatric SLE - 177 pSLE, & 38 developed OI (3.4/100PY). Most common OIs: Candida (27%), Aspergillus (13.5%), CMV (13.5%) - lung & skin mostly. Risk factors: Pulse steroids, Dz activity (SLEDAI-2K ≥11) https://t.co/0zjDOnDCEh https://t.co/H7JZ56ItDY
Dr. John Cush
Tweet
Should You Use Low Dose Naltrexone?
A recent review of 105 studies and 15 randomized controlled trials of LDN found that, across a range of disorders (chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatological conditions, post-infectious https://t.co/lmjJoGlFAZ
Dr. John Cush
Tweet
RHEUM SURVEY>> How do you assess cutaneous lupus activity or treatment responses? Click here>> https://t.co/1HWC4DV55h https://t.co/X8MUqjxqys
American College of Rheumatology
Tweet
Congratulations to John J. Cush, MD, of @RheumNow, recipient of the ACR Distinguished Clinician Scholar Award. The award recognizes his outstanding contributions to clinical medicine, scholarship, and education in rheumatology. #ACR26 https://t.co/9wWLjQNnxH
Dr. John Cush
Tweet
Lancet: A Public Health Policy Call Out for Osteoarthritis
In honor of World Arthritis Day (Oct. 12th), The Lancet has published a public Health Policy report is to "outline a globally relevant roadmap to address the osteoarthritis identity problem, focusing on health policy https://t.co/XTRDJnOEGn
Dr. John Cush
Tweet
Placebo beats probiotics in PsA. And nearly 90% of well-controlled RA patients may be able to cut their targeted therapy dose in half.
Dr. Jack Cush breaks down the findings worth a closer look in this week's RheumNow podcast, Troubles with ‘Gut Feelings’.
Probiotics in PsA: https://t.co/Aqy4HxGHbU
Dr. John Cush
Tweet
Yale researchers propose repurposing the epilepsy drug, lacosamide, to treat osteoarthritis. In animal models, delivered as a hydrogel conjugate IA, improved cartilage repair, slowed deterioration, & reduced pain. Chosen as it blocks Sodium channels, esp Nav1.7 involved in pain https://t.co/ERJ2xPEyzl
Dr. John Cush
Tweet
Market info: Ankylosing Spondylitis market size in USA estimated at $3.3 billion USD in 2020 & is expected to increase 8.36% annually from 2019–2032. US prevalence of AS in 2020 was 1,300,971 cases https://t.co/EAginmKFF9 https://t.co/2Ye4Gk1awT
Dr. John Cush
Tweet
Italian GISEA (early RA) registry = 1304 pts Rx w/ JAK inhibitors. Retention rates at 6, 12, & 24 mos = 81%, 75%, & 61%. Low retention w/ baseline GC, high Dz activity, & pain. https://t.co/kKZmTHmEUb https://t.co/JlUUrFIU4G
Dr. John Cush
Tweet
Single center study of Probiotics in #PsA showed no benefit. 66 moderately active PsA pts (PASDAS>3.2) on stable Tx: Rx probiotic vs PBO x 12 wks. 56 pts analyzed, PASDAS <3 responders: 43% probiotic vs 65% PBO (P 0.167), w/ no change in gut permeability markers or stool https://t.co/0JUZ8SrRuw
Dr. John Cush
Tweet
92 early (<2 yrs) systemic sclerosis pts were treated with #MTX; 79% diffuse SSc. At 3 mos, 34% of dcSSc ≥25% reduction in mRSS - increasing to 612% a@ 24 mos (29% at 24 mos ITT w/ non-responder imputation). GC did not improve skin. Dz progression seen w/ 75% of MTX monoTx D/C https://t.co/w5Gc3ntej0
Dr. John Cush
Tweet
"Perfection is not attainable, but if we chase perfection we can catch excellence."
- Vince Lombardi https://t.co/KgQGp6mKlH
Dr. John Cush
Tweet
Symptomatic hand OA (HOA) increased signif in past decade in the Netherlands (esp women & older adults). PCP EHR study of 1.8 million Dutch patients ≥30 yrs. Betw 2013 & 2023, prevalence incr 65% (5.7 to 9.4%); incidence rose 20% (7.1 to 8.5/1000PY) https://t.co/HyqdwJ70y4 https://t.co/7fBngLO5w0
Dr. John Cush
Tweet
Univ Toronto lupus clinic study of 165 #SLE pts w/ Bx-proven LN (age 35.3 yrs; Dz dur 6.2 years). Half on antimalarial Rx. Being on HCQ did not alter Renal Bx outcomes (prolif GN, NIH AI, NIH CI, IFTA score. (But is known to improve renal outcomes) https://t.co/oQ0CgK7rXm https://t.co/PZX31wOPmL
Dr. John Cush
Tweet
Can DMARD Doses Be Safely Reduced for RA Patients?
Close to 90% of patients with rheumatoid arthritis (RA) well controlled on targeted therapies were able to take 50% dosage reductions without experiencing worsened disease activity in a randomized trial, South Korean https://t.co/MyjZdRaGb4
Dr. John Cush
Tweet
In early RA, initial b/tsDMARDs are better than MTX. Metanalysis of 29 RCTs (13387 pts), Vs MTX alone, initial b/tsDMARDs + MTX signif incr DAS28 remission 2 6 mos (RR 1.62) & 12 mos (RR 1.54). Benefits greater w/ higher baseline Dz, seropositivity https://t.co/exwVOc08xR https://t.co/00UXGTGPaH
article
Dr. Jack Cush reviews this week's news from RheumNow.com, including: placebo trumps controversial therapies, the dynamics of disease activity, fuse the big toe, and patients don’t appreciate being told “it's all in your head”!
Dr. John Cush
Tweet
Kenneth G. Saag, M.D., https://t.co/TJOX58X5d5., Named North American Editor-in-Chief of Osteoporosis International; Dr. Saag also will oversee Archives of Osteoporosis in collaboration with the International Osteoporosis Foundation (IOF). Ken is a professor of medicine and https://t.co/KouJoStW5C

Poster Hall
